CAPOTEN

Compare CAPOTEN  to:
Compare
Compare

Generic Name for CAPOTEN

Captopril 12.5mg, 25mg, 50mg, 100mg; scored tabs.

Legal Classification:

Rx

Pharmacological Class for CAPOTEN

ACE inhibitor.

Manufacturer of CAPOTEN

Par Pharmaceutical, Inc.

Indications for CAPOTEN

Hypertension.

Adult dose for CAPOTEN

Take 1 hr before meals. Initially 25mg 2–3 times daily. After 1–2 wks may increase to 50mg 2–3 times daily. If control unsatisfactory, see literature. Titrate to usual dose after several days. Monitor closely for 1st 2 wks and if dose increased; max 450mg/day. Renal impairment: see literature.

Children's dosing for CAPOTEN

See literature.

Contraindications for CAPOTEN

History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for CAPOTEN

Renal impairment. Salt/volume depletion. CHF. Dialysis (esp. high-flux membrane). Aortic stenosis. Monitor WBCs and renal function in renal and collagen vascular disease. Monitor for hyperkalemia in diabetics and renal insufficiency. Surgery. Discontinue if neutropenia, agranulocytosis, angioedema, or laryngeal edema occurs. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for CAPOTEN

Caution with K+-sparing diuretics and K+-containing supplements. May be antagonized by NSAIDs. Potentiated by diuretics, β-blockers, adrenergic antagonists. May increase lithium levels. May produce false (+) urinary acetone.

Adverse Reactions for CAPOTEN

Headache, dysgeusia, rash, pruritus, dizziness, fatigue, cough, proteinuria, nephritis, GI upset, hyperkalemia, hyponatremia, back pain, tachycardia, dry mouth, jaundice, somnolence, sweating, sinusitis, impotence, angioedema.

How is CAPOTEN supplied?

Tabs 25mg, 50mg—100, 1000
12.5mg, 100mg—100

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.